FDA panel endorses first-of-a-kind cancer blood test from Grail
The panel voted 7-2 to recommend the first multi-cancer blood test, saying it may help find cancers earlier despite unresolved accuracy questions.
- On Wednesday, a Federal advisory panel to The FDA recommended the agency approve Grail's Galleri blood test, marking the first federal advisory group to back an experimental multi-cancer detection test for people 50 and older.
- Grail's DNA-based Galleri test uses a single blood draw to identify signals from up to 50 cancer types, positioned as additive to standardized screenings like mammograms and colonoscopies rather than a replacement.
- The advisory committee reviewed major clinical studies involving more than 140,000 patients in the National Health System and over 35,000 North American patients, though experts noted the test often failed to detect early-stage cancers in these trials.
- Ultimate approval by The FDA could facilitate widespread adoption and insurance reimbursement for the test, which currently costs $949; a final decision is expected in a few months, though the agency is not bound by the panel's advice.
- Notably Phil Castle, director of the National Cancer Institute's Division of Cancer Prevention, warned that "Routine approval and broad population rollout would risk harm and waste resources," while Michelle Tarver of The FDA emphasized technologies with such reach demand careful evaluation.
32 Articles
32 Articles
Panellists expressed reservations about the tests supporting the Grail Galleri test, designed to detect cancer in its early stages
FDA panel narrowly backs multi-cancer blood test despite doubts it works
A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and Drug Administration (FDA) advisers Wednesday, even as several doubted it works.
FDA panel endorses first-of-a-kind cancer blood test from Grail - WSVN 7News | Miami News, Weather, Sports
WASHINGTON (AP) — Federal health advisers on Wednesday endorsed a blood test designed to spot signs of various cancers in apparently healthy people while warning...
FDA-endorsed blood test can spot early signs of more than 50 types of cancer, drugmaker says
The U.S. Food and Drug Administration (FDA) endorsed a blood test designed to spot early signs of dozens of cancers despite concerns about how definitive the test’s results may be, the Associated Press reported.
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
